Cargando…

Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study

OBJECTIVES: The efficacy of tivantinib may have some potential in treating MET-high hepatocellular carcinoma, and we aim to compare tivantinib with placebo for the treatment of MET-high hepatocellular carcinoma. METHODS: Several databases including PubMed, Cochrane Library, Web of Science, EBSCO, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Guang-li, Guo, Bian-qin, Wu, Li-xiang, Shen, Yan-xi, Xie, Tingting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197645/ https://www.ncbi.nlm.nih.gov/pubmed/35711496 http://dx.doi.org/10.1155/2022/1976788

Ejemplares similares

Development of Tivantinib as Treatment for Hepatocellular Carcinoma
por: Au, Jennifer, et al.
Publicado: (2013)

The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis
por: Wang, Yubin, et al.
Publicado: (2023)

Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
por: Pievsky, Daniel, et al.
Publicado: (2016)

Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma
por: Xiang, Qingfeng, et al.
Publicado: (2015)

The efficacy and safety of tivantinib in the treatment of solid tumors: a systematic review and meta-analysis
por: Zhang, Hao, et al.
Publicado: (2017)

Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107
por: Twardowski, Przemyslaw W., et al.
Publicado: (2017)

Tivantinib alleviates inflammatory diseases by directly targeting NLRP3
por: Huang, Yi, et al.
Publicado: (2023)

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
por: Santoro, A, et al.
Publicado: (2013)

Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
por: Zhao, Shankun, et al.
Publicado: (2021)

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
por: Rimassa, Lorenza, et al.
Publicado: (2016)

Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors
por: Okusaka, Takuji, et al.
Publicado: (2015)

A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia
por: Kuenzi, Brent M., et al.
Publicado: (2019)

Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma
por: Wei, Kai, et al.
Publicado: (2019)

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
por: Tolaney, Sara M., et al.
Publicado: (2015)

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
por: Puzanov, Igor, et al.
Publicado: (2014)

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
por: Wu, Zhuo-Xun, et al.
Publicado: (2020)

Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer
por: Broggini, Massimo, et al.
Publicado: (2013)

Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling
por: Wu, Yukun, et al.
Publicado: (2019)

Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib
por: Agwa, Eberechi S, et al.
Publicado: (2014)

Targeting the Pro-Survival Protein MET with Tivantinib (ARQ 197) Inhibits Growth of Multiple Myeloma Cells()()
por: Zaman, Shadia, et al.
Publicado: (2015)

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors
por: Kummar, Shivaani, et al.
Publicado: (2021)

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
por: Baljevic, Muhamed, et al.
Publicado: (2017)

Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non–small-cell lung cancer: A meta-analysis based on randomized controlled trials
por: Deng, Huan, et al.
Publicado: (2020)

Efficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysis
por: Yan, Lun-Jie, et al.
Publicado: (2022)

Diagnostic accuracy of midkine on hepatocellular carcinoma: A meta-analysis
por: Zhang, Bo-han, et al.
Publicado: (2019)

Association between the methylenetetrahydrofolate reductase C677T polymorphism and hepatocellular carcinoma risk: a meta-analysis
por: Jin, Fei, et al.
Publicado: (2009)

Meta-Analysis of Microsomal Epoxide Hydrolase Gene Polymorphism and Risk of Hepatocellular Carcinoma
por: Zhong, Jian-Hong, et al.
Publicado: (2013)

Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis
por: Sun, Tingting, et al.
Publicado: (2018)

Association of GSTP1 and P16 promoter methylation with the risk of HBV-related hepatocellular carcinoma: a meta-analysis
por: Li, Qin, et al.
Publicado: (2018)

Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis
por: Tian, Xin, et al.
Publicado: (2015)

Prognostic value of CD44 expression in patients with hepatocellular carcinoma: meta-analysis
por: Luo, Yangkun, et al.
Publicado: (2016)

Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1
por: Lu, Shuai, et al.
Publicado: (2015)

Epidermal Growth Factor Gene Polymorphism and Risk of Hepatocellular Carcinoma: A Meta-Analysis
por: Zhong, Jian-Hong, et al.
Publicado: (2012)

Diagnostic Performance of Des-γ-carboxy Prothrombin for Hepatocellular Carcinoma: A Meta-Analysis
por: Zhu, Rong, et al.
Publicado: (2014)

The Association between MTHFR Gene Polymorphisms and Hepatocellular Carcinoma Risk: A Meta-Analysis
por: Qin, Xue, et al.
Publicado: (2013)

Hsa_circ_0013290 Acts as Cancer-Promoting Gene in Hepatocellular Carcinoma
por: Luo, Xi, et al.
Publicado: (2021)

Prognostic prediction of the platelet-to-lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis
por: Li, De-Zhao, et al.
Publicado: (2022)

Osteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-analysis
por: Sun, Tingting, et al.
Publicado: (2018)

CD147 as a Novel Prognostic Biomarker for Hepatocellular Carcinoma: A Meta-Analysis
por: Peng, Fei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_adk71s6chsp3vg649m51e1nvv9